Official Press Release by The Insight Partners

North America Pharmaceutical Excipients Market is expected to reach US$ 8,494.9 Million by 2034

Published: August 06, 2026
Industry: Life Sciences
Authored By: Mrinal Kerhalkar
  • The North America Pharmaceutical Excipients Market is projected to grow from US$ 4,906.6 Mn in 2025 to US$ 8,494.9 Mn by 2034, at a CAGR of 6.4%
  • Key growth factors include Surging Demand for Generic Medications and Advanced Formulations , Increasing Research and Development Efforts in Novel Excipients , and Growing Biopharmaceuticals and Biosimilars , strengthening adoption across multiple end-use sectors.
  • The market is witnessing a shift toward Growing Advancements in Multifunctional and Nanotechnology Excipients and Rising Adoption of Biologics and Novel Delivery Systems , while Shift Toward Patient-Centric and Continuous Manufacturing is creating new opportunities for industry participants.

Base Value (2025)

US$ 4,906.6 Mn

Projected (2034)

US$ 8,494.9 Mn

CAGR (2026-2034)

6.4%

According to The Insight Partners' research, the North America Pharmaceutical Excipients Market was valued at US$ 4,906.6 Million in 2025 and is expected to reach US$ 8,494.9 Million by 2034, registering a CAGR of 6.4% from 2026 to 2034.

Growing advancements in multifunctional and nanotechnology excipients and rising adoption of biologics and novel delivery systems are among the critical factors attributed to drive the North America pharmaceutical excipients market.

In the market, advancements in multifunctional and nanotechnology excipients are paving the way for more sophisticated drug formulations that enhance stability, bioavailability, and targeted delivery. Multifunctional excipients, which combine multiple roles such as solubilization, lubrication, and controlled release within a single material, streamline manufacturing processes and reduce the need for multiple additives, leading to cleaner and more efficient formulations. Lipid-based multifunctional excipients such as self-emulsifying drug delivery systems (SEDDS) are used in oral tablets for poorly water-soluble drugs, allowing for rapid dispersion in the gastrointestinal tract and improved absorption of compounds such as itraconazole. Nanotechnology takes this by engineering excipients at the nanoscale, where particles exhibit unique properties such as high surface area and tunable porosity. Nano-sized excipients, such as polymeric nanoparticles derived from chitosan or silica, enable precise encapsulation of active pharmaceutical ingredients (APIs), protecting them from degradation and facilitating site-specific release. A notable example is the use of lipid nanoparticles in mRNA vaccines, where excipients such as ionizable lipids not only stabilize the genetic material but also promote endosomal escape for effective cellular uptake. These innovations address challenges in treating hydrophobic drugs and biologics, offering enhanced therapeutic outcomes with minimal side effects. As regulatory bodies embrace these technologies, pharmaceutical companies are exploring hybrid excipients that integrate nanotechnology with natural polymers, such as cellulose nanocrystals modified for mucoadhesive properties in nasal sprays for Alzheimer's therapeutics. This shift not only optimizes drug performance but also supports sustainable practices by reducing excipient quantities. These advancements promise to transform chronic disease management, from oncology to cardiology, by enabling excipients that adapt to physiological conditions, fostering a more patient-centric pharmaceutical landscape.

On the contrary, stringent and complex regulatory frameworks hamper the growth of the North America pharmaceutical excipients market.

North America Pharmaceutical Excipients Market Segmentation Analysis:

  • By Type, the North America Pharmaceutical Excipients Market is segmented into Bioresorbable Polymers and Lipids and Liposome Based Formulation, Oleochemicals, Sugars, Cellulose, Starches, Petrochemicals, Plant Proteins Polyols and Cyclodextrins, Inorganic Chemicals, and Others. The Cellulose segment is projected to expand at a CAGR of 6.2% during 2026 - 2034.
  • By Oleochemicals For Type, the North America Pharmaceutical Excipients Market is segmented into Fatty Alcohols, Metal Stearates, Glycerin, and Other Oleochemicals. The Fatty Alcohols segment is projected to expand at a CAGR of 6.9% during 2026 - 2034.
  • By Sugars For Type, the North America Pharmaceutical Excipients Market is segmented into Actual Sugars, Sugar Alcohols, and Artificial Sweeteners. The Actual Sugars segment is projected to expand at a CAGR of 5.5% during 2026 - 2034.
  • By Cellulose For Type, the North America Pharmaceutical Excipients Market is segmented into Microcrystalline Cellulose, Cellulose Ethers, and Carboxymethylcellulose and Croscarmellose Sodium. The Microcrystalline Cellulose segment is projected to expand at a CAGR of 6.3% during 2026 - 2034.
  • By Starches For Type, the North America Pharmaceutical Excipients Market is segmented into Modified Starches, Dried Starch, and Converted Starch and Pregelatinized Starch. The Modified Starches segment is projected to expand at a CAGR of 4.7% during 2026 - 2034.
  • By Petrochemicals For Type, the North America Pharmaceutical Excipients Market is segmented into Glycols, Povidones, Mineral Hydrocarbons, and Other Petrochemicals. The Glycols segment is projected to expand at a CAGR of 6.2% during 2026 - 2034.
  • By Inorganic Chemicals For Type, the North America Pharmaceutical Excipients Market is segmented into Magnesium and Calcium Carbonate, Calcium and Aluminum Phosphate, Silicon Dioxide, Titanium Dioxide, and Other Inorganic Chemicals. The Calcium and Aluminum Phosphate segment is projected to expand at a CAGR of 7.8% during 2026 - 2034.
  • By Clinical Indication, the North America Pharmaceutical Excipients Market is segmented into Cancer, Metabolic, Infectious Disease, Dental, Ophthalmic, Cardiovascular, and Other Clinical Indications. The Cancer segment is projected to expand at a CAGR of 7.2% during 2026 - 2034.
  • By Functionality, the North America Pharmaceutical Excipients Market is segmented into Coloring Agents and Coating Agents, Sweetner and Flavoring Agents, Suspending and Viscosity Agents, Preservative and Controlled Release, Antioxidant and Oil, Tablet Filler and Diluent, Binder and Compression and Granulating Agents, Emulsifiers, Surfactants, and Others. The Tablet Filler and Diluent segment is projected to expand at a CAGR of 6.1% during 2026 - 2034.
  • By Surfactants For Functionality, the North America Pharmaceutical Excipients Market is segmented into Polyoxyethylene Hydrogenated Castor Oil, Polysorbates, Sodium Dodecyl Sulfate, and Other Surfactants. The Polysorbates segment is projected to expand at a CAGR of 7.4% during 2026 - 2034.
  • By Application, the North America Pharmaceutical Excipients Market is segmented into Oral, Injectable, Topical, and Others. The Oral segment is projected to expand at a CAGR of 6.5% during 2026 - 2034.
  • By Oral For Application, the North America Pharmaceutical Excipients Market is segmented into Tablet, Capsule, Liquid, and Others. The Tablet segment is projected to expand at a CAGR of 7.1% during 2026 - 2034.
  • By Capsule For Oral, the North America Pharmaceutical Excipients Market is segmented into Hard Gel and Soft Gel. The Hard Gel segment is projected to expand at a CAGR of 6.5% during 2026 - 2034.
  • By End User, the North America Pharmaceutical Excipients Market is segmented into Pharma Industries, Biopharma Industries, Animal Health, and Other End User. The Pharma Industries segment is projected to expand at a CAGR of 6.5% during 2026 - 2034.

By country, the North America Pharmaceutical Excipients Market is categorized into the United States, Canada, and Mexico. The United States is projected to expand at a CAGR of 6.5% during 2026 - 2034.

Key players operating in the Pharmaceutical Excipients Market are BASF SE, JRS PHARMA GmbH & Co KG, Roquette Freres SA, Avantor Inc, Archer-Daniels-Midland Co, Evonik Industries AG, Merck KGaA, The Dow Chemical Co, The Lubrizol Corp, Ashland Inc, and MEGGLE GmbH & Co KG, among others.

  • In October 2025, Ashland added high-purity sucrose and parenteral applications to its injectables portfolio and highlighted its expanded low-nitrite pharmaceutical excipients during CPHI Frankfurt, held on October 28-30, and AAPS PharmSci 360, San Antonio, TX, held in November.
  • In October 2025, Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, celebrated the launch of its latest novel pharmaceutical excipient: KLEPTOSE Crysmeb methyl-beta-cyclodextrin. This unique solution harnesses the high encapsulating performance of specifically modified methyl-beta-cyclodextrin to enhance the solubility and stability of a wide range of active (bio)pharmaceutical ingredients.